3.31Open3.31Pre Close0 Volume1 Open Interest1.00Strike Price0.00Turnover591.96%IV5.90%PremiumJan 17, 2025Expiry Date3.07Intrinsic Value100Multiplier9DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type0.9747Delta0.0153Gamma1.30Leverage Ratio-0.0119Theta0.0002Rho1.27Eff Leverage0.0004Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet